Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestwick Buyout Scores Huntington’s Drug For Biovail

This article was originally published in The Pink Sheet Daily

Executive Summary

Canadian company affirms prior deal that gave Ovation the U.S. rights to Xenazine.

You may also be interested in...



Santhera Licenses North American Rights For Parkinson's Drug To Biovail

The transaction is the Canadian drug maker's latest in a string of deals designed to increase its footing in the CNS market.

Santhera Licenses North American Rights For Parkinson's Drug To Biovail

The transaction is the Canadian drug maker's latest in a string of deals designed to increase its footing in the CNS market.

Biovail Locks Up Global Rights To Xenazine With Cambridge Deal

The $230 million deal doubles Biovail's investment in Xenazine and is the latest indication that there is more to this is Huntington's chorea therapy than meets the eye.

Related Content

Topics

UsernamePublicRestriction

Register

PS068358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel